NCT04463602View on ClinicalTrials.gov

Desidustat in the Management of COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

July 25, 2020

Primary Completion Date

January 25, 2021

Study Completion Date

March 31, 2021

Conditions
COVID-19
Interventions
DRUG

Desidustat

100 mg once daily

OTHER

Standard of Care

Standard of care as per local authority

Trial Locations (1)

Unknown

Avant Sante Site 1, Monterrey

All Listed Sponsors
lead

Zydus Lifesciences Limited

INDUSTRY

NCT04463602 - Desidustat in the Management of COVID-19 Patients | Biotech Hunter | Biotech Hunter